1.2Fluorinated aromatic ring position
The carbon at Q1 retains its two ring bonds and forms an exocyclic C–F bond. Q2 supplies an aromatic nitrogen acceptor while the C–F bond changes the local electron distribution.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The carbon at Q1 retains its two ring bonds and forms an exocyclic C–F bond. Q2 supplies an aromatic nitrogen acceptor while the C–F bond changes the local electron distribution.
The sulfur forms two single bonds to the atoms flanking Q3 and closes the ring at the same position. The longer bonds at sulfur change the local ring geometry.
Sulfur forms a single bond to each atom flanking Z and carries two sulfonyl oxygens. The group connects the same attachment points and supplies two hydrogen-bond acceptors.
The nitrogen at Z bonds to the first carbon of an —CH2CH2OH chain and retains its two scaffold bonds. The terminal hydroxyl supplies a hydrogen-bond donor and acceptor two carbons from nitrogen.
The scaffold bonds directly to the sulfur of an —S(═O)2CH3 group. The two sulfonyl oxygens supply hydrogen-bond acceptors, and the group withdraws electron density from the attachment site.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A carbonyl group replaces the methylene at Z while keeping the same two ring attachments. The carbonyl carbon occupies the Z position, and the oxygen projects from the ring. The carbonyl oxygen acts as a hydrogen-bond acceptor and introduces a local dipole at the bridge.
A matched series connects the scaffold to a cyclohexyl ring through a carbon linker at R2. The series uses zero, one, or two methylene units, giving direct cyclohexyl, cyclohexylmethyl, and cyclohexylethyl attachments. All other scaffold positions stay fixed so that the series varies the attachment distance and the number of rotatable bonds.
A multiwell cell assay combines the adenine analogs with a mitochondria-targeted fluorescent reporter that changes its emission ratio when mitochondria reach acidic compartments. Each plate contains compound-treated wells, solvent controls, and cells lacking PINK1. A plate reader measures both emission channels, and the assay compares their ratio across the matched cell groups.
A parallel artificial membrane permeability assay places a lipid-coated porous filter between donor and receiver wells. The donor wells contain dissolved adenine analogs, and the receiver wells contain buffer. Liquid chromatography measures compound concentrations on both sides after incubation, and the receiver concentration provides the transferred amount used to estimate apparent permeability.
Molecular graph software stores the scaffold with atom labels at each variable position and generates candidate structures by changing one position at a time. The software checks atom valences and removes duplicate structures using canonical molecular graph identifiers. It exports compound pairs and assigns each pair to adjacent wells for side-by-side measurement.
Z contains a carbonyl carbon with a double bond to oxygen and single bonds to the two flanking atoms. The carbonyl oxygen serves as a hydrogen-bond acceptor.
The —O(CH2)nCy1 arrangement uses n = 2 and cyclohexyl as Cy1. The spacer connects the ether oxygen to a cyclohexyl ring carbon through two consecutive methylene groups.
R13 is methyl in an —N(CH3)CH2Cy1 side chain with n = 1. The linker nitrogen bonds to the scaffold, the methyl carbon, and the methylene carbon leading to Cy1.
Cy1 is a 5-cyanopyridin-3-yl group. The pyridine ring attaches through carbon 3 and carries one cyano substituent at carbon 5.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
when X1 is —O—, —S— or —NR34—, then: R1 and R2 are each independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C3alkyl), C3-C8 cycloalkyl, —CH2F, —CHF2 and —CF3; or R1 and R2, together with the carbon atom to which they are both attached, form a chemically feasible C3 to C6 alkylene ring; or R1 and R2, together with one another and the carbon atom to which they are both attached, form a C═O group;B · US 2011/0098468 A1 · ¶ 13
Rc and Rd each independently is: hydrogen; or alkyl; or Rc and Rd together form ═O, ═S, or ═NRf, wherein Rf is hydrogen, alkyl, or —ORg, wherein Rg is hydrogen or alkyl; or one of R2 and R3 together with one of Rc and Rd together with the atoms to which they are attached may form a four to six membered ring that optionally includes an additional heteroatom selected from O, N and S; and Re is hydrogen or alkyl.A · US 2009/0099236 A1 · claim 28
Rb and Rc are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, Rd is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, Rd is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino.A · US 2009/0099236 A1 · ¶ 87
R1 is phenyl, pyridinyl, or indolyl each of which is optionally substituted with one, two, three or four substituents each of which is independently selected from alkyl, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkoxyalkyl or hydroxyalkyl; and one of R2 and R3 is hydrogen while the other is alkyl, preferably methyl.A · US 2009/0099236 A1 · ¶ 244
each R19 is a substituent on the aryl or heteroaryl ring to which it is attached, and is independently selected from the group consisting of H, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, —OH, halogen, —CN, —NO2, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —O—(C1-C6 alkyl), —O—(C3-C8 cycloalkyl), —COOR12, —CONR21R22, —OC(O)NR21R22, —OC(O)R12, —NR21R22, —NR21COR12, —NR21CO2R12, —NR21CONR21R22, —NR21SO2R15 and —S(O)n6R15;B · US 2011/0098468 A1 · ¶ 34
Ar is indolyl optionally substituted with one, two, three or four substituents each independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, alkylsulfonyloxy, —(CH2)q—S(O)rRf; —(CH2)q—NRgRh; or —(CH2)q—C(═O)—NRgRh; where q is 0 or 1, r is from 0 to 2, and each of Rf, Rg, and Rh is independently hydrogen or alkyl;A · US 2009/0099236 A1 · ¶ 244
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof.A · US 2009/0099236 A1 · ¶ 83
where, n1 is 0 to 5; and G is H, —CF3, —CHF2, —CH2F, —OH, —O—(C1-C6 alkyl), —OCH2F, —OCHF2, —OCF3, —OCH2CF3, —O—(C3-C8 cycloalkyl), —O—(C1-C6)alkyl(C3-C8 cycloalkyl), —NR13R14, —SO2NR13R14, —NR12SO2R13, —NR12C(O)R14, —NR12C(O)OR13, —NR12(C(O)NR13R14), —C(O)NR13R14, —C(O)OR13, —C3-C8 cycloalkyl, (R19)r-aryl, (R19)r-heteroaryl, —OC(O)R14, —OC(O)NR13R14, —C(═NOR14)(R13), —C(O)R13, —C(OR12)(R13)(R14), heterocycloalkenyl optionally substituted by 1 to 4 substituents independentlyB · US 2011/0098468 A1 · ¶ 20
R1 and R2 are independently selected from the group consisting of H, C1-C6 alkyl or hydroxyl (C1-C3alkyl), C3-C8 cycloalkyl; —CH2F, CHF2, —CF3, R3 is H, C1-C5alkyl, hydroxyC1-C3alkyl, C3-C8cycloalkyl, CH2F, CF2H or CF3;B · US 2011/0098468 A1 · claim 41
An empty cell means only that no passage was reproduced there.
In particular, compounds of the present invention are useful for treatment of diseases associated with monoamine reuptake inhibitors.A · US 2009/0099236 A1 · ¶ 2
Dual reuptake inhibitors of serotonin and norepinephrine also offer potential treatments for disorders and disease states of the urinary tract, and for pain and inflammation.A · US 2009/0099236 A1 · ¶ 4
It would be beneficial to provide a NK1 antagonist that is potent, selective, and possesses beneficial therapeutic and pharmacological properties, and good metabolic stability.B · US 2011/0098468 A1 · ¶ 6
It would further be beneficial to provide a NK1 antagonist that is effective for treating a variety of physiological disorders, symptoms and diseases while minimizing side effects.B · US 2011/0098468 A1 · ¶ 6
patent.fyi, US 2026/0356842 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356842/, SHA-256 25db7f6f49ca86bc7f2c772bd5eb54163ebcb27f0c88d46db2595443d5328d3f